Senate HELP Committee Leadership: Sizing Up The Candidates
Sen. Chris Dodd has a relatively limited record in pharmaceutical legislation - especially in comparison to the late Sen. Ted Kennedy - but his initiatives include establishing incentives for pediatric drug development and supporting increased government oversight in the areas of drug safety and direct-to-consumer advertising
You may also be interested in...
FDA hopes that internal process improvements will result in "more clever" requests to companies for pediatric studies under the Best Pharmaceuticals for Children Act
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials